Abcam, ab263348, Human SLC12A9 knockout HeLa cell lysate

Size: 1Kit
SLC12A9 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-SLC12A9, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SLC12A9 also known as CCC9 is part of the cation-chloride cotransporter family. It is a protein with an approximate mass of 120 kDa. This transporter is involved in moving ions across cell membranes particularly sodium potassium and chloride ions playing a significant role in maintaining cellular homeostasis. SLC12A9 is expressed in various tissues including the kidney and brain suggesting its importance across different physiological systems.
Biological function summary
The protein facilitates ion transport within cells contributing to osmoregulation and volume control. Although SLC12A9 is not a central part of any known large protein complex its ion transport functionality indicates it might interact with other membrane proteins involved in similar regulatory roles. This interaction helps modulate cell volume and osmolality which influences cell survival and function.
Pathways
SLC12A9 plays a role in the cellular signaling and homeostasis pathways. It is particularly associated with the WNK (With No Lysine) kinases-pathway which regulates electrolyte balance and blood pressure. In this context SLC12A9 has relations with other transporters like NKCC1 and KCC2 which also participate in the same ion transport and regulatory processes indicating cooperative interactions in maintaining cellular ionic balance.
Several studies have linked SLC12A9 to hypertension due to its role in regulating blood pressure via ion transport. Additionally research suggests its potential involvement in neurological disorders given its expression in brain tissues. Mutations or dysregulation of SLC12A9 could affect other related proteins such as WNK kinases contributing to these pathologies by altering ion transport dynamics and impacting overall cellular function.